Cargando…

Biomarkers of PEGylated Liposomal Doxorubicin-Induced Hypersensitivity Reaction in Breast Cancer Patients Based on Metabolomics

This study aimed to analyze and discuss the biomarkers of PEGylated liposomal doxorubicin (PLD) injection-induced hypersensitivity reactions (HSRs) in advanced breast cancer patients. Fourteen patients from Sun Yat-sen Memorial Hospital were included in the study between April 15th, 2020 and April 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhuang, Wei, Lai, Xiuping, Mai, Qingxiu, Ye, Suiwen, Chen, Junyi, Liu, Yanqiong, Wang, Jingshu, Li, Siming, Huang, Yanqing, Qin, Tao, Hu, Hai, Wu, Junyan, Yao, Herui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068896/ https://www.ncbi.nlm.nih.gov/pubmed/35529437 http://dx.doi.org/10.3389/fphar.2022.827446

Ejemplares similares

Exploring the Use of Pegylated Liposomal Doxorubicin (Caelyx(®)) as Pressurized Intraperitoneal Aerosol Chemotherapy
por: Robella, Manuela, et al.
Publicado: (2019)

Pegylated liposomal doxorubicin in ovarian cancer
por: Green, Andrew E, et al.
Publicado: (2006)

Pegylated liposomal doxorubicin in ovarian cancer
por: Strother, Robert, et al.
Publicado: (2009)

Pegylated liposomal doxorubicin for myeloid neoplasms
por: Zhang, Cheng, et al.
Publicado: (2019)

Cardiac Safety in Breast Cancer Patients Receiving Pegylated Liposome Doxorubicin Sequential Anti-HER2 Monoclonal Antibody Therapy
por: Huang, Ping, et al.
Publicado: (2022)

Pegylated liposomal doxorubicin in the management of ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2010)

A tale of the two PEGylated liposomal doxorubicins
por: Chou, Hunghsueh, et al.
Publicado: (2015)

Pegylated Liposomal Doxorubicin-induced Palmar-plantar Erythrodysesthesia
por: Moreira-Barros, Joana, et al.
Publicado: (2018)

Prolonged use of pegylated liposomal doxorubicin in gynecologic malignancies
por: Yost, S., et al.
Publicado: (2019)

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
por: Yuan, Zhen, et al.
Publicado: (2021)

Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma
por: Ghaferi, Mohsen, et al.
Publicado: (2022)

Folate-Targeted PEGylated Magnetoliposomes for Hyperthermia-Mediated Controlled Release of Doxorubicin
por: Cintra, Emílio R., et al.
Publicado: (2022)

Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma
por: Udhrain, Ashish, et al.
Publicado: (2007)

Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer
por: Pisano, Carmela, et al.
Publicado: (2013)

Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial
por: Wang, Tiantian, et al.
Publicado: (2022)

Serious stomatitis and esophagitis: a peculiar mucous reaction induced by pegylated liposomal doxorubicin
por: Ma, Han, et al.
Publicado: (2015)

Cardiovascular adverse events associated with cyclophosphamide, pegylated liposomal doxorubicin, vincristine, and prednisone with or without rituximab ((R)-CDOP) in non-Hodgkin’s lymphoma: A systematic review and meta-analysis
por: Lu, Bin, et al.
Publicado: (2022)

Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma
por: Schmidinger, M, et al.
Publicado: (2001)

Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi’s sarcoma
por: Cainelli, Francesca, et al.
Publicado: (2009)

Pegylated liposomal doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo
por: Yuan, Y, et al.
Publicado: (2008)

Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer
por: Anders, Carey K., et al.
Publicado: (2013)

The role of size in PEGylated liposomal doxorubicin biodistribution and anti‐tumour activity
por: Dadpour, Saba, et al.
Publicado: (2022)

Establishing an evaluation index system of nursing quality for clinical drug trials: A Delphi study
por: Chen, Junyi, et al.
Publicado: (2023)

Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma
por: Nik, Maryam Ebrahimi, et al.
Publicado: (2019)

Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure
por: Savani, Malvi, et al.
Publicado: (2019)

Cardiac Safety of Pegylated Liposomal Doxorubicin After Conventional Doxorubicin Exposure in Patients With Sarcoma and Breast Cancer
por: Alhaja, Maher, et al.
Publicado: (2023)

Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar
por: Fracasso, P M, et al.
Publicado: (2005)

The Way that PEGyl-DSPC Liposomal Doxorubicin Particles Penetrate into Solid Tumor Tissue
por: Pan, Xing Qing, et al.
Publicado: (2006)

Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)
por: O’Donnell, Robert T., et al.
Publicado: (2009)

A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
por: Huober, Jens, et al.
Publicado: (2010)

Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma
por: Wei, Minyan, et al.
Publicado: (2015)

Pulmonary Fibrosis after Pegylated Liposomal Doxorubicin in Elderly Patient with Cutaneous Angiosarcoma
por: Mazzotta, Marco, et al.
Publicado: (2016)

Pegylated liposomal-encapsulated doxorubicin in cutaneous composite lymphoma: A case report
por: Wollina, Uwe, et al.
Publicado: (2016)

Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice
por: Stark, Christoffer, et al.
Publicado: (2018)

Inhibition of Exosome Release Sensitizes U937 Cells to PEGylated Liposomal Doxorubicin
por: Hekmatirad, Shirin, et al.
Publicado: (2021)

Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer
por: Markman, Maurie
Publicado: (2011)

Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma
por: Shah, Jatin J, et al.
Publicado: (2009)

Modeling pegylated liposomal doxorubicin-induced hand-foot syndrome and intestinal mucositis in zebrafish
por: Chen, Yau-Hung, et al.
Publicado: (2014)

EXTRAVASATION OF PEGYLATED-LIPOSOMAL DOXORUBICIN: FAVORABLE OUTCOME AFTER IMMEDIATE SUBCUTANEOUS ADMINISTRATION OF CORTICOSTEROIDS
por: MITSUMA, AYAKO, et al.
Publicado: (2012)

Outcomes of AIDS-associated Kaposi sarcoma in Mozambique after treatment with pegylated liposomal doxorubicin
por: Coldiron, Matthew E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sii6mm4f3vl1usftr8va1fcagm